EPIZYME INC (EPZM)

US29428V1044 - Common Stock

1.47  -0.02 (-1.34%)

After market: 1.47 0 (0%)

Fundamental Rating

2

Taking everything into account, EPZM scores 2 out of 10 in our fundamental rating. EPZM was compared to 588 industry peers in the Biotechnology industry. EPZM has a bad profitability rating. Also its financial health evaluation is rather negative. EPZM shows excellent growth, but is valued quite expensive already.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EPZM has reported negative net income.
In the past 5 years EPZM always reported negative net income.
EPZM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -78.64%
ROE N/A
ROIC -67.61%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -370.05%
PM (TTM) -391.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EPZM is destroying value.
EPZM has more shares outstanding than it did 1 year ago.
EPZM has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -8.10, we must say that EPZM is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of -11.48 indicates that EPZM is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -11.48
Debt/FCF N/A
Altman-Z -8.1
ROIC/WACC-5.62
WACC12.02%

2.3 Liquidity

A Current Ratio of 5.35 indicates that EPZM has no problem at all paying its short term obligations.
A Quick Ratio of 5.19 indicates that EPZM has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.35
Quick Ratio 5.19

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.33% over the past year.
EPZM shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.65%.
The Revenue has been growing by 36.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q66.67%
Revenue 1Y (TTM)62.65%
Revenue growth 3Y19.92%
Revenue growth 5Y36.12%
Revenue growth Q2Q111.59%

3.2 Future

Based on estimates for the next years, EPZM will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.01% on average per year.
The Revenue is expected to grow by 57.70% on average over the next years. This is a very strong growth
EPS Next Y43.15%
EPS Next 2Y23.07%
EPS Next 3Y16.89%
EPS Next 5Y8.01%
Revenue Next Year28.63%
Revenue Next 2Y45.71%
Revenue Next 3Y52.93%
Revenue Next 5Y57.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPZM. In the last year negative earnings were reported.
Also next year EPZM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.76

4.3 Compensation for Growth

A more expensive valuation may be justified as EPZM's earnings are expected to grow with 16.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.07%
EPS Next 3Y16.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPZM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EPIZYME INC

NASDAQ:EPZM (8/11/2022, 7:00:01 PM)

After market: 1.47 0 (0%)

1.47

-0.02 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap247.44M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.64%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -370.05%
PM (TTM) -391.89%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity -11.48
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.35
Quick Ratio 5.19
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y43.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)62.65%
Revenue growth 3Y19.92%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y